SEC Comment Letter for Oyster Point Pharma, Inc. (CIK 0001720725) — Nov 10, 2020
Oyster Point Pharma, Inc. (CIK 0001720725)
Date: Nov. 10, 2020 · CIK: 0001720725 · Accession: 0000000000-20-010768
AI Filing Summary & Sentiment
File numbers found in text: 333-249881
Letter
United States securities and exchange commission logo November 10, 2020 Jeffrey Nau President and Chief Executive Officer Oyster Point Pharma, Inc. 202 Carnegie Center, Suite 109 Princeton, New Jersey 08540 Re:Oyster Point Pharma, Inc. Registration Statement on Form S-3 Filed November 5, 2020 File No. 333-249881 Dear Dr. Nau: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Div Gupta, Esq.
Show Raw Text
United States securities and exchange commission logo
November 10, 2020
Jeffrey Nau
President and Chief Executive Officer
Oyster Point Pharma, Inc.
202 Carnegie Center, Suite 109
Princeton, New Jersey 08540
Re:Oyster Point Pharma, Inc.
Registration Statement on Form S-3
Filed November 5, 2020
File No. 333-249881
Dear Dr. Nau:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Div Gupta, Esq.